This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers

Tuesday, May 14, 2019

Submitted by


Source Name: The New England Journal of Medicine


Deepak L. Bhatt, Charles V. Pollack, Jeffrey I. Weitz, Lisa K. Jennings, Sherry Xu, Susan E. Arnold, Bret R. Umstead, Michael C. Mays, John S. Lee

Ticagrelor (Brilinta), an oral P2Y12 inhibitor, is an agent used in combination with aspirin for dual antiplatelet therapy after coronary interventions. It's antiplatelet function cannot be reversed by platelet transfusion. The authors evaluated the efficacy of IV PB2452, a monoclonal antibody, in reversing ticagrelor's antiplatelet effect in a randomized, double-blind, placebo-controlled, phase 1 trial in healthy volunteers. The administration of PB2452 resulted in reversal of ticagrelor's antiplatelet effect within 5 minutes of infusion of the former, and this effect was sustained. There were minimal adverse events associated with this reversal agent.

Add comment

Log in or register to post comments